Design Therapeutics, Inc. (DSGN)
Nasdaq: DSGN · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 9, 2026 | Mar 10, 2025 | Mar 19, 2024 | Mar 14, 2023 | Mar 10, 2022 | · |
| Revenue | 0 | 0 | · | · | · | 226 |
| Research and development | 59,129 | 44,350 | 57,063 | 48,613 | 24,778 | 6,060 |
| General and administrative | 20,338 | 18,033 | 21,127 | 18,980 | 11,053 | 2,496 |
| Total operating expenses | 79,467 | 62,383 | 78,190 | 67,593 | 35,831 | 8,556 |
| Operating income | -79,467 | -62,383 | -78,190 | -67,593 | -35,831 | -8,330 |
| Interest and investment income | 9,675 | 12,795 | 11,328 | · | · | · |
| Other income (expense), net | · | · | 11,328 | 4,285 | 298 | 50 |
| Income tax expense | 0 | 0 | · | · | · | · |
| Net income including non-controlling interests | -69,792 | -49,588 | -66,862 | -63,308 | -35,533 | -8,280 |
| Net income | -69,792 | -49,588 | -66,862 | -63,308 | -35,533 | -8,280 |
| Earnings per share, basic | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | · |
| Earnings per share, diluted | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | · |
| Earnings per share, basic and diluted | · | · | · | · | -0.77 | -0.52 |
| Weighted average shares, basic | 57,330,192 | 56,587,142 | 55,984,670 | 55,707,517 | 45,936,235 | · |
| Weighted average shares, diluted | 57,330,192 | 56,587,142 | 55,984,670 | 55,707,517 | 45,936,235 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 45,936,235 | 15,796,674 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted